What's Happening?
The Advanced Research Projects Agency for Health (ARPA-H) has allocated up to $27.7 million to a collaborative project led by the Innovative Genomics Institute at the University of California, Berkeley. This initiative, part of the THRIVE program, aims
to develop affordable gene-editing therapies for children with inborn errors of immunity (IEI). The project, known as AEGIS, seeks to create a scalable solution by delivering gene editors directly to patients' bone marrow using lipid nanoparticles. This approach could eliminate the need for chemotherapy and stem cell transplantation, which are currently required for genetic therapies. The team includes experts from various institutions, including UCLA, the University of Utah, and Mayo Clinic, and aims to treat 10 children within the next five years.
Why It's Important?
This initiative addresses a significant unmet medical need, as current genetic therapies for IEI are limited and costly, often exceeding $1 million per child. By developing a more efficient and less invasive method of delivering gene-editing therapies, the project could drastically reduce costs and improve accessibility. This could lead to a paradigm shift in how rare genetic diseases are treated, potentially benefiting thousands of children diagnosed with IEI each year in the U.S. The project also leverages regulatory momentum from the FDA, aiming to reduce the time and cost of developing personalized gene editors.
What's Next?
The project plans to treat 10 children over the next five years, with the goal of reducing the development time for personalized gene editors to under three months and the cost to below $200,000. The team will continue to innovate in gene editor engineering, delivery methods, and regulatory processes. Success in this initiative could pave the way for broader applications of gene-editing technologies in treating other genetic disorders, potentially influencing future healthcare policies and funding priorities.
